MYB and breast carcinoma: Therefore, we conclude that maintenance of MYB expression can overcome the sensitivity of MCF-7 cells to CDK9i, which is in turn consistent with MYB down-regulation being a primary mediator of ER+veMYB+ve breast cancer cell killing by this class of drugs.